Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Valneva ( (VALN) ) has issued an announcement.
On August 18, 2025, Valneva SE announced that Health Canada has granted marketing authorization for its chikungunya vaccine, IXCHIQ®, for individuals aged 12 and older. This approval marks a significant milestone as chikungunya poses a growing public health risk, with recent outbreaks in countries like Brazil, India, and China. The vaccine’s authorization in Canada follows its earlier approval in Brazil and complements its adolescent label extension received in Europe. The approval is based on positive Phase 3 data showing a high and sustained immune response, and it is expected to accelerate the vaccine’s licensure in other regions, enhancing protection against the chikungunya virus.
The most recent analyst rating on (VALN) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects a challenging financial position with consistent losses and cash flow issues. Despite strong technical momentum and positive earnings call highlights, the company’s valuation is constrained by negative earnings. The most significant factors are the financial performance and technical analysis, with earnings call insights providing additional context.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The company focuses on providing first-, best-, or only-in-class vaccine solutions and has a strong track record of advancing multiple vaccines from early R&D to approvals. Valneva currently markets three proprietary travel vaccines and is developing vaccine candidates against Lyme disease, Shigella, Zika virus, and other global public health threats.
Average Trading Volume: 63,351
Technical Sentiment Signal: Buy
Current Market Cap: $950.7M
For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.